NP Core Meeting 6–9pm Friday, September 25 Room: Sullivan AB

FINAL AGENDA

Light refreshments will be provided.

6:00 **Welcome and introductory remarks**
Julia Kofler, MD CHAIR, NP CORE STEERING COMMITTEE; NP CORE LEADER, UNIVERSITY OF PITTSBURGH

- NP Form version 10 — issues and updates
- NP Steering Committee rotation

6:05 **NIA update**
Creighton Phelps, PhD DEPUTY DIRECTOR, DIVISION OF NEUROSCIENCE, NIA/NIH, AND DIRECTOR, ADC PROGRAM

6:10 **NACC update**
Walter A. Kukull, PhD DIRECTOR, NATIONAL ALZHEIMER'S COORDINATING CENTER

6:20 **DIAN and ADNI neuropathology core update**
Nigel Cairns, PhD NP CORE LEADER, WASHINGTON UNIVERSITY IN ST. LOUIS

6:25 **Update on performance characteristics of revised NIA-AA guidelines**
Thomas J. Montine, MD, PhD DIRECTOR, UNIVERSITY OF WASHINGTON

6:45 **Scientific symposium part 1: Update on classification of Tauopathies**

6:45 **PART**
Peter Nelson, MD, PhD NP CORE LEADER, UNIVERSITY OF KENTUCKY
John Crary, MD, PhD MOUNT SINAI

7:20 **Glial tauopathy**
Dennis Dickson, MD NP CORE LEADER, MAYO CLINIC

7:40 **CTE**
Ann McKee, MD NP CORE LEADER, BOSTON UNIVERSITY

8:00 **Coffee break**

8:10 **Scientific symposium part 2: Tau imaging**

8:10 **In vitro binding of PET tau ligands**
Milos Ikonomovic, MD NEUROPATHOLOGY AND GENETICS CORE, UNIVERSITY OF PITTSBURGH

8:30 **Neuropathology correlates of PET tau imaging**
Teresa Gomez-Isla, MD, PhD CLINICAL CORE LEADER, MASSACHUSETTS ADRC

8:50 **Q&A**

9:00 **Adjourn**

NACC NP v10 forms – common errors

- **ABC scores entered but ADNC scores missing/not assessed**
- **ADNC scores inconsistent with ABC scores**
- **TDP antibody and FTLD-TDP entries inconsistent (not assessed/value entered)**

→ **New error checks created (Thanks, Lilah Besser)**

NACC NP v10 forms – common errors

- **Thal phase missing**
- **TDP information missing**

→ **Free antibodies available!**

- **A-beta NAB228 (Eddie Lee, John Trojanowski)**
- **Alpha-synuclein SYN303 (Eddie Lee, John Trojanowski)**
- **p-tau PHF1 (Peter Davies)**
- **p-TDP 1D3 (Manuela Neumann)**

Steering committee rotation

NP Core Meeting 6–9pm Friday, September 25 Room: Sullivan AB

FINAL AGENDA

Light refreshments will be provided.

6:00 **Welcome and introductory remarks**
Julia Kofler, MD CHAIR, NP CORE STEERING COMMITTEE; NP CORE LEADER, UNIVERSITY OF PITTSBURGH

- NP Form version 10 — issues and updates
- NP Steering Committee rotation

6:05 **NIA update**
Creighton Phelps, PhD DEPUTY DIRECTOR, DIVISION OF NEUROSCIENCE, NIA/NIH, AND DIRECTOR, ADC PROGRAM

6:10 **NACC update**
Walter A. Kukull, PhD DIRECTOR, NATIONAL ALZHEIMER'S COORDINATING CENTER

6:20 **DIAN and ADNI neuropathology core update**
Nigel Cairns, PhD NP CORE LEADER, WASHINGTON UNIVERSITY IN ST. LOUIS

6:25 **Update on performance characteristics of revised NIA-AA guidelines**
Thomas J. Montine, MD, PhD DIRECTOR, UNIVERSITY OF WASHINGTON

6:45 **Scientific symposium part 1: Update on classification of Tauopathies**

6:45 **PART**
Peter Nelson, MD, PhD NP CORE LEADER, UNIVERSITY OF KENTUCKY
John Crary, MD, PhD MOUNT SINAI

7:20 **Glial tauopathy**
Dennis Dickson, MD NP CORE LEADER, MAYO CLINIC

7:40 **CTE**
Ann McKee, MD NP CORE LEADER, BOSTON UNIVERSITY

8:00 **Coffee break**

8:10 **Scientific symposium part 2: Tau imaging**

8:10 **In vitro binding of PET tau ligands**
Milos Ikonomovic, MD NEUROPATHOLOGY AND GENETICS CORE, UNIVERSITY OF PITTSBURGH

8:30 **Neuropathology correlates of PET tau imaging**
Teresa Gomez-Isla, MD, PhD CLINICAL CORE LEADER, MASSACHUSETTS ADRC

8:50 **Q&A**

9:00 **Adjourn**

6:45 Scientific symposium part 1: Update on classification of Tauopathies

6:45 **PART**
Peter Nelson, MD, PhD NP CORE LEADER, UNIVERSITY OF KENTUCKY
John Crary, MD, PhD MOUNT SINAI

7:20 **Glial tauopathy**
Dennis Dickson, MD NP CORE LEADER, MAYO CLINIC

7:40 **CTE**
Ann McKee, MD NP CORE LEADER, BOSTON UNIVERSITY

8:00 **Coffee break**

8:10 Scientific symposium part 2: Tau imaging

8:10 **In vitro binding of PET tau ligands**
Milos Ikonomovic, MD NEUROPATHOLOGY AND GENETICS CORE, UNIVERSITY OF PITTSBURGH

8:30 **Neuropathology correlates of PET tau imaging**
Teresa Gomez-Isla, MD, PhD CLINICAL CORE LEADER, MASSACHUSETTS ADRC

8:50 **Q&A**

9:00 **Adjourn**

For discussion

b. FTLD-tau subtype

(CHECK ONE BOX PER ROW)	No	Yes	Not assessed	Missing/unknown
1. FTLD-tau (PiD)	☐ 0	☐ 1	☐ 8	☐ 9
2. Other 3R tauopathy (Includes *MAPT* mutation tauopathy)	☐ 0	☐ 1	☐ 8	☐ 9
3. FTLD-tau (CBD)	☐ 0	☐ 1	☐ 8	☐ 9
4. FTLD-tau (PSP)	☐ 0	☐ 1	☐ 8	☐ 9
5. Argyrophilic grains	☐ 0	☐ 1	☐ 8	☐ 9
6. Other 4R tauopathy (Includes sporadic multiple systems tauopathy, globular glial tauopathy, *MAPT* mutation tauopathy)	☐ 0	☐ 1	☐ 8	☐ 9
7. Chronic traumatic encephalopathy	☐ 0	☐ 1	☐ 8	☐ 9
8. Amyotrophic lateral sclerosis (ALS)/ Parkinsonism-dementia complex of Guam	☐ 0	☐ 1	☐ 8	☐ 9
9. Tangle dominant disease	☐ 0	☐ 1	☐ 8	☐ 9
10. Other 3R + 4R tauopathy (Includes unclassifiable, focal, glial only, *MAPT* mutation tauopathy, NOS)	☐ 0	☐ 1	☐ 8	☐ 9

For discussion

b. FTLD-tau subtype

(CHECK ONE BOX PER ROW)	No	Yes	Not assessed	Missing/unknown
1. FTLD-tau (PiD)	☐ 0	☐ 1	☐ 8	☐ 9
2. Other 3R tauopathy (Includes *MAPT* mutation tauopathy)	☐ 0	☐ 1	☐ 8	☐ 9
3. FTLD-tau (CBD)	☐ 0	☐ 1	☐ 8	☐ 9
4. FTLD-tau (PSP)	☐ 0	☐ 1	☐ 8	☐ 9
5. Argyrophilic grains	☐ 0	☐ 1	☐ 8	☐ 9
6. Other 4R tauopathy (Includes sporadic multiple systems tauopathy, globular glial tauopathy, *MAPT* mutation tauopathy)	☐ 0	☐ 1	☐ 8	☐ 9
7. Chronic traumatic encephalopathy	☐ 0	☐ 1	☐ 8	☐ 9
8. Amyotrophic lateral sclerosis (ALS)/ Parkinsonism-dementia complex of Guam	☐ 0	☐ 1	☐ 8	☐ 9
9. Tangle dominant disease **PART**	☐ 0	☐ 1	☐ 8	☐ 9
10. Other 3R + 4R tauopathy (Includes unclassifiable, focal, glial only, *MAPT* mutation tauopathy, NOS) **ARTAG**	☐ 0	☐ 1	☐ 8	☐ 9

For discussion

Table 1 Minimum recommended brain regions to be sampled and evaluated

Region	AD Neuropathologic Change			LBD	VBI and HS
	A Stain for Aβ/amyloid plaques [57]	**B** Stain for NFTs [14,15]	**C** Stain for NPs [41]	Stain for LBs	H&E
Medulla including DMV				1°: IHC or H&E[a]	VBI
Pons including LC				1°: IHC or H&E[a]	VBI
Midbrain including SN	3°: if 2° is +			1°: IHC or H&E[a]	VBI
Cerebellar cortex and dentate n.	3°: if 2° is +				VBI
Thalamus and subthalamic n.[b]					MVL
Basal ganglia at level of AC with basal nucleus of Meynert[b]	2°: if 1° is +	Consider[c]			MVL
Hippocampus and EC[b]	2°: if 1° is +[d]	Yes	Consider[c]	2°: IHC in at least one if 1° +	HS
Cingulate, anterior					VBI
Amygdala				1°: IHC[a]	VBI
Middle frontal gyrus[b]	1°[d]	Yes	Yes	2°: IHC in at least one if 1° +	MVL
Superior and middle temporal gyri[b]	1°[d]	Yes	Yes		MVL
Inferior parietal lobule[b]	1°[d]	Yes	Yes		MVL
Occipital cortex (BA 17 and 18)[b]	Consider[c]	Yes	Consider[c]		MVL
WM at ACA, MCA, and PCA watershed					Consider[c]

For discussion

Table 1 Minimum recommended brain regions to be sampled and evaluated

Region	AD Neuropathologic Change			LBD	VBI and HS
	A Stain for Aβ/amyloid plaques [57]	**B** Stain for NFTs [14,15]	**C** Stain for NPs [41]	Stain for LBs	H&E
Medulla including DMV				1°: IHC or H&E[a]	VBI
Pons including LC				1°: IHC or H&E[a]	VBI
Midbrain including SN	3°: if 2° is +			1°: IHC or H&E[a]	VBI
Cerebellar cortex and dentate n.	3°: if 2° is +				VBI
Thalamus and subthalamic n.[b]					MVL
Basal ganglia at level of AC with basal nucleus of Meynert[b]	2°: if 1° is +	Consider[c]			MVL
Hippocampus and EC[b]	2°: if 1° is +[d]	Yes	Consider[c]	2°: IHC in at least one if 1° +	HS
Cingulate, anterior					VBI
Amygdala				1°: IHC[a]	VBI
Middle frontal gyrus[b]	1°[d]	Yes	Yes	2°: IHC in at least one if 1° +	MVL
Superior and middle temporal gyri[b]	1°[d]	Yes	Yes		MVL
Inferior parietal lobule[b]	1°[d]	Yes	Yes		MVL
Occipital cortex (BA 17 and 18)[b]	Consider[c]	Yes	Consider[c]		MVL
WM at ACA, MCA, and PCA watershed					Consider[c]

6:45 Scientific symposium part 1: Update on classification of Tauopathies

6:45 **PART**
Peter Nelson, MD, PhD NP CORE LEADER, UNIVERSITY OF KENTUCKY
John Crary, MD, PhD MOUNT SINAI

7:20 **Glial tauopathy**
Dennis Dickson, MD NP CORE LEADER, MAYO CLINIC

7:40 **CTE**
Ann McKee, MD NP CORE LEADER, BOSTON UNIVERSITY

8:00 **Coffee break**

8:10 Scientific symposium part 2: Tau imaging

8:10 **In vitro binding of PET tau ligands**
Milos Ikonomovic, MD NEUROPATHOLOGY AND GENETICS CORE, UNIVERSITY OF PITTSBURGH

8:30 **Neuropathology correlates of PET tau imaging**
Teresa Gomez-Isla, MD, PhD CLINICAL CORE LEADER, MASSACHUSETTS ADRC

8:50 **Q&A**

9:00 **Adjourn**